10 research outputs found
Magnetic field - temperature phase diagram of quasi-two-dimensional organic superconductor lambda-(BETS)_2 GaCl_4 studied via thermal conductivity
The thermal conductivity kappa of the quasi-two-dimensional (Q2D) organic
superconductor lambda-(BETS)_2 GaCl_4 was studied in the magnetic field H
applied parallel to the Q2D plane. The phase diagram determined from this bulk
measurement shows notable dependence on the sample quality. In dirty samples
the upper critical field H_{c2} is consistent with the Pauli paramagnetic
limiting, and a sharp change is observed in kappa(H) at H_{c2 parallel}. In
contrast in clean samples H_{c2}(T) shows no saturation towards low
temperatures and the feature in kappa(H) is replaced by two slope changes
reminiscent of second-order transitions. The peculiarity was observed below ~
0.33T_c and disappeared on field inclination to the plane when the orbital
suppression of superconductivity became dominant. This behavior is consistent
with the formation of a superconducting state with spatially modulated order
parameter in clean samples.Comment: 10 pages, 8 figures, new figure (Fig.5) and references added, title
change
Scaling properties of the magnetic-field-induced specific heat of superconducting UBe
We report on measurements of the low-temperature specific heat Cp(T, B) of the unconventional superconductor UBe13 in magnetic fields up to 7 T. At Bâ2 T, a substantial change in the magnetic-field dependence of the temperature derivative of the magnetic-field induced contribution to the electronic specific heat CH(T, B), resulting from the flow of supercurrents around the vortices, is observed, suggesting a crossover between two different regions in the superconducting phase diagram of UBe13. For fields B >2 T, CH(T, B) exhibits a scaling behavior with respect to TB-1/2, which provides substantial evidence for the existence of point nodes in the quasiparticle excitation spectrum of the superconductor
Pressure dependence of the upper critical field of the heavy fermion superconductor UBe13
no abstrac
Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries
WOS: 000468732700018PubMed ID: 31054483Background and aims: One of the objectives of the ESC-EORP EUROASPIRE V survey is to determine how well European guidelines on the management of dyslipidaemias are implemented in coronary patients. Methods: Standardized methods were used by trained technicians to collect information on 7824 patients from 130 centers in 27 countries, from the medical records and at a visit at least 6 months after hospitalization for a coronary event. All lipid measurements were performed in one central laboratory. Patients were divided into three groups: on high-intensity LDL-C-lowering-drug therapy (LLT), on low or moderate-intensity LLT and on no LLT. Results: At the time of the visit, almost half of the patients were on a high-intensity LLT. Between hospital discharge and the visit, LLT had been reduced in intensity or interrupted in 20.8% of the patients and had been started or increased in intensity in 11.7%. In those who had interrupted LLT or had reduced the intensity, intolerance to LLT and the advice of their physician were reported as the reason why in 15.8 and 36.8% of the cases, respectively. LDL-C control was better in those on a high-intensity LLT compared to those on low or moderate intensity LLT. LDL-C control was better in men than women and in patients with self-reported diabetes. Conclusions: The results of the EUROASPIRE V survey show that most coronary patients have a less than optimal management of LDL-C. More professional strategies are needed, aiming at lifestyle changes and LLT adapted to the need of the individual patient.ESC - EORP; AmgenAmgen; Eli LillyEli Lilly; PfizerPfizer; SanofiSanofi-Aventis; Ferrer; Novo NordiskNovo NordiskThe EUROASPIRE V survey was carried out under the auspices of the ESC - EORP. Since the start of EORP, the following companies have supported the programme: Amgen, Eli Lilly, Pfizer, Sanofi, Ferrer and Novo Nordisk. The sponsors of the EUROASPIRE surveys had no role in the design, data collection, data analysis, data interpretation, decision to publish, or writing the manuscript
Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries
Background and aims: One of the objectives of the ESC-EORP EUROASPIRE V
survey is to determine how well European guidelines on the management of
dyslipidaemias are implemented in coronary patients.
Methods: Standardized methods were used by trained technicians to
collect information on 7824 patients from 130 centers in 27 countries,
from the medical records and at a visit at least 6 months after
hospitalization for a coronary event. All lipid measurements were
performed in one central laboratory. Patients were divided into three
groups: on high-intensity LDL-C-lowering-drug therapy (LLT), on low or
moderate-intensity LLT and on no LLT.
Results: At the time of the visit, almost half of the patients were on a
high-intensity LLT. Between hospital discharge and the visit, LLT had
been reduced in intensity or interrupted in 20.8% of the patients and
had been started or increased in intensity in 11.7%. In those who had
interrupted LLT or had reduced the intensity, intolerance to LLT and the
advice of their physician were reported as the reason why in 15.8 and
36.8% of the cases, respectively. LDL-C control was better in those on
a high-intensity LLT compared to those on low or moderate intensity LLT.
LDL-C control was better in men than women and in patients with
self-reported diabetes.
Conclusions: The results of the EUROASPIRE V survey show that most
coronary patients have a less than optimal management of LDL-C. More
professional strategies are needed, aiming at lifestyle changes and LLT
adapted to the need of the individual patient
Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry.
AIMS: To evaluate how recommendations of European guidelines regarding pharmacological and non-pharmacological treatments for heart failure (HF) are adopted in clinical practice. METHODS AND RESULTS: The ESC-HF Long-Term Registry is a prospective, observational study conducted in 211 Cardiology Centres of 21 European and Mediterranean countries, members of the European Society of Cardiology (ESC). From May 2011 to April 2013, a total of 12 440 patients were enrolled, 40.5% with acute HF and 59.5% with chronic HF. Intravenous treatments for acute HF were heterogeneously administered, irrespective of guideline recommendations. In chronic HF, with reduced EF, renin-angiotensin system (RAS) blockers, beta-blockers, and mineralocorticoid antagonists (MRAs) were used in 92.2, 92.7, and 67.0% of patients, respectively. When reasons for non-adherence were considered, the real rate of undertreatment accounted for 3.2, 2.3, and 5.4% of the cases, respectively. About 30% of patients received the target dosage of these drugs, but a documented reason for not achieving the target dosage was reported in almost two-thirds of them. The more relevant reasons for non-implantation of a device, when clinically indicated, were related to doctor uncertainties on the indication, patient refusal, or logistical/cost issues. CONCLUSION: This pan-European registry shows that, while in patients with acute HF, a large heterogeneity of treatments exists, drug treatment of chronic HF can be considered largely adherent to recommendations of current guidelines, when the reasons for non-adherence are taken into account. Observations regarding the real possibility to adhere fully to current guidelines in daily clinical practice should be seriously considered when clinical practice guidelines have to be written
Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries
Background and aims: One of the objectives of the ESC-EORP EUROASPIRE V
survey is to determine how well European guidelines on the management of
dyslipidaemias are implemented in coronary patients.
Methods: Standardized methods were used by trained technicians to
collect information on 7824 patients from 130 centers in 27 countries,
from the medical records and at a visit at least 6 months after
hospitalization for a coronary event. All lipid measurements were
performed in one central laboratory. Patients were divided into three
groups: on high-intensity LDL-C-lowering-drug therapy (LLT), on low or
moderate-intensity LLT and on no LLT.
Results: At the time of the visit, almost half of the patients were on a
high-intensity LLT. Between hospital discharge and the visit, LLT had
been reduced in intensity or interrupted in 20.8\% of the patients and
had been started or increased in intensity in 11.7\%. In those who had
interrupted LLT or had reduced the intensity, intolerance to LLT and the
advice of their physician were reported as the reason why in 15.8 and
36.8\% of the cases, respectively. LDL-C control was better in those on
a high-intensity LLT compared to those on low or moderate intensity LLT.
LDL-C control was better in men than women and in patients with
self-reported diabetes.
Conclusions: The results of the EUROASPIRE V survey show that most
coronary patients have a less than optimal management of LDL-C. More
professional strategies are needed, aiming at lifestyle changes and LLT
adapted to the need of the individual patient